Renal Transplantation
Conditions
Keywords
renal transplant, panel reactive antibody, sensitization, simvastatin, immunological
Brief summary
Patients with panel reactive antibodies have many difficulties to find a crossmatch-negative kidney for transplantation and are at the risk of post transplantation rejection more than other transplanted patients. We evaluated the effect of simvastatin on PRA and post transplant outcome of these sensitized patients. We also performed a descriptive study.
Detailed description
The presence of panel reactive antibodies (PRAs) in the sera of renal transplant candidates is associated with hyperacute or delayed humoral immune responses against the graft after transplantation . In addition, these sensitized patients wait for a long time to find a cross-match negative kidney for renal transplantation . As a result, some modalities have been used for desensitization including plasmapheresis and intravenous immunoglobulin (IVIG) in combination with immunosuppressive drugs . However, recently, the use of statins such as simvastatin, pravastatin and etc. has been proposed to be safer and more effective for desensitization .
Interventions
DRUGsimvastatin
20 mg simvastatin daily
Sponsors
Shiraz University of Medical Sciences
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. patients with ESRD on hemodialysis or peritoneal dialysis 2. On the waiting list for renal transplant 3. PRA more than 25%
Exclusion criteria
1. Pregnant women 2. Patients who need ongoing blood products 3. Patients taking other therapies to decrease PRA 4. Patients listed for multi-organ transplant other than kidney 5. Patients with liver failure
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| effect of simvastatin on panel reactive antibody | 12 months |
Countries
Iran
Outcome results
None listed